Revista Española de Cardiología - Suplemento - vol 20 ; fasc B ; 2020

M. Anguita et al. / Rev Esp Cardiol Supl. 2020; 20(B) :1-46 41 23. Sociedad Española de Medicina de Familia y Comunitaria. Procesos asistenciales compartidos entre atención primaria y cardiología, 2015. Disponible en: https:// secardiologia.es/images/publicaciones/libros/procesos-asistenciales-compartidos- entre-atencion-primaria-y-cardiologia.pdf. Consultado 3 Feb 2020. 24. Pérez de Isla L, Díaz Sánchez S, Pagola J, et al. Consensus document of the SEMI, semFYC, SEN, and SEC on focused cardiac ultrasound in Spain. Rev Esp Cardiol. 2018;71:935-940. 25. Rice H, Say R, Betihavas V. The effect of nurse-led education on hospitalisation, readmission, quality of life and cost in adults with heart failure. A systematic review. Patient Educ Couns. 2018;101:363-374. 26. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol. 2004;44:810-819. 27. Feltner C, Jones CD, Cene CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta- analysis. Ann Intern Med. 2014;160:774-784. 28. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:1169-1186. 29. Srisuk N, Cameron J, Ski CF, Thompson DR. Randomized controlled trial of family- based education for patients with heart failure and their carers. J Adv Nurs. 2017;73:857-870. 30. Van Spall HGC, Rahman T, Mytton O, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail. 2017;19: 1427-1443. 31. Van Spall HGC, Lee SF, Xie F, et al. Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: The PACT- HF randomized clinical trial. JAMA. 2019;321:753-761. 32. Srisuk N, Cameron J, Ski CF, Thompson DR. Heart failure family-based education: a systematic review. Patient Educ Couns. 2016;99:326-338. 33. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev. 2019;(1):CD003331. 34. Yancy CW. The uncertainty of sodium restriction in heart failure: we can do better than this. JACC Heart Fail. 2016;4:39-41. 35. Butler J, Papadimitriou L, Georgiopoulou V, Skopicki H, Dunbar S, Kalogeropoulos A. Comparing sodium intake strategies in heart failure: rationale and design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) study. Circ Heart Fail. 2015;8:636-645. 36. Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced salt intake for heart failure: a systematic review. JAMA Intern Med. 2018;178:1693-1700. 37. Dos Reis Padilha G, Sanches Machado d’Almeida K, Ronchi Spillere S, Correa Souza G. Dietary patterns in secondary prevention of heart failure: a systematic review. Nutrients. 2018;10. 38. Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovasc Disord. 2006;6:43. 39. Rajati F, Sadeghi M, Feizi A, Sharifirad G, Hasandokht T, Mostafavi F. Self-efficacy strategies to improve exercise in patients with heart failure: A systematic review. ARYA Atheroscler. 2014;10:319-333. 40. Jonkman NH, Westland H, Groenwold RH, et al. What are effective program characteristics of self-management interventions in patients with heart failure? An individual patient data meta-analysis. J Card Fail. 2016;22:861-871. 41. JonkmanNH, WestlandH, Groenwold RH, et al. Do self-management interventions work in patients with heart failure? An individual patient data meta-analysis. Circulation. 2016;133:1189-1198. 42. Jaarsma T, Arestedt KF, Martensson J, Dracup K, Stromberg A. The European Heart Failure Self-care Behaviour scale revised into a nine-item scale (EHFScB-9): a reliable and valid international instrument. Eur J Heart Fail. 2009;11:99-105. 43. Bueno H, Lobos JM, Murga N, Díaz S. Procesos asistenciales compartidos entre atención primaria y cardiología. En: Cardiología. Madrid: semFYC; 2015. 44. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis. JAMA. 2004;291:1358-1367. 45. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure. Cochrane Database Syst Rev. 2019;(1):CD002752. 46. Propuesta conjunta SEC-SEMI para la organización compartida de nuevos modelos de atención al paciente con insuficiencia cardiaca en base a programas y unidades de insuficiencia cardiaca. 2016. Disponible en: https://www.fesemi.org/sites/ default/files/documentos/publicaciones/consenso-sec-semi.pdf. Consultado 3 Feb 2020. 47. Comunicación/relación entre Atención Primaria y Cardiología. 2017. Disponible en: https://secardiologia.es/images/institucional/sec-calidad/SEC-AP__Manual_ de_Comunicaci%C3%B3n_Versi%C3%B3n_final.pdf. Consultado 3 Feb 2020. 48. Decálogo de transiciones al alta hospitalaria tras ingreso por insuficiencia cardiaca. 2019. Disponible en: https://secardiologia.es/insuficiencia?start=140. 49. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med. 1994;154:433-437. 50. Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence on hospitalizations and mortality in heart failure. J Card Fail . 2011;17:664-669. 51. Bagchi AD, Esposito D, Kim M, Verdier J, Bencio D. Utilization of, and adherence to, drug therapy among medicaid beneficiaries with congestive heart failure. Clin Ther . 2007;29:1771-1783. 52. Niriayo YL, Kumela K, Kassa TD, Angamo MT. Drug therapy problems and contributing factors in the management of heart failure patients in Jimma University Specialized Hospital, Southwest Ethiopia. PLoS One. 2018;13: e0206120. 53. Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Spec Pharm. 2014;20:741-755. 54. Wu JR, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients who have heart failure: a review of the literature. Nurs Clin North Am. 2008;43:133- 153; vii-viii. 55. Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials. J Am Heart Assoc. 2016;5. 56. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to promote patient utilisation of cardiac rehabilitation. Cochrane Database Syst Rev. 2019;(2):CD007131. 57. Sackett DL, Haynes RB, Gibson ES, et al. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1975;1: 1205-1207. 58. Val Jimenez A, Amoros Ballestero G, Martinez Visa P, Fernandez Ferre ML, Leon Sanroma M. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. Aten Primaria. 1992;10:767-770. 59. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-e239. 60. Savarese G, Musella F, D’Amore C, et al. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail. 2014;2:148-158. 61. Khan MS, Siddiqi TJ, Usman MS, et al. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta- analysis. Int J Cardiol. 2018;263:80-87. 62. Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail. 2017;5:280-286. 63. Aimo A, Vergaro G, Ripoli A, et al. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail. 2017;5:287-296. 64. Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol. 2018;72:2309-2320. 65. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 2003;108:833-838. 66. Lupon J, de Antonio M, Galan A, et al. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc. 2013;88:234-243. 67. Salzano A, Marra AM, D’Assante R, et al. Biomarkers and imaging: complementary or subtractive? Heart Fail Clin. 2019;15:321-331. 68. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017;23:628-651. 69. Masson S, Batkai S, Beermann J, et al. Circulating microRNA-132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur J Heart Fail. 2018;20:78-85. 70. Bayes-Genis A, Lanfear DE, de Ronde MWJ, et al. Prognostic value of circulating microRNAs on heart failure-related morbidity and mortality in two large diverse cohorts of general heart failure patients. Eur J Heart Fail. 2018;20:67-75. 71. Yoon JY, Yang DH, Cho HJ, et al. Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure. Korean J Intern Med. 2018;34:811-834. 72. D’Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003;41:1805-1811. 73. Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both sides of the heart: a retrospective analysis. Int J Cardiol. 2011;149:80-82. 74. Nunez J, Llacer P, Bertomeu-Gonzalez V, et al. Carbohydrate antigen-125-guided therapy in acute heart failure: CHANCE-HF: a randomized study. JACC Heart Fail. 2016;4:833-843. 75. Nunez J, Nunez E, Bayes-Genis A, et al. Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure. Eur Heart J Acute Cardiovas Care. 2017;6:685-696. 76. Grande D, Leone M, Rizzo C, et al. A multiparametric approach based on NT- proBNP, ST2, and galectin3 for stratifying one year prognosis of chronic heart failure outpatients. J Cardiovasc Dev Dis. 2017;4. 77. Lupon J, Gavidia-Bovadilla G, Ferrer E, et al. Dynamic trajectories of left ventricular ejection fraction in heart failure. J Am Coll Cardiol. 2018;72:591-601. 78. Marwick TH, Shah SJ, Thomas JD. Myocardial strain in the assessment of patients with heart failure: a review. JAMA Cardiol. 2019. 79. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;9:684-694.